Aktis Oncology, Inc. (AKTS) Form 10-Q — May 11, 2026
Aktis Oncology, Inc. reported a net loss of $18.3 million for the three months ended March 31, 2026, compared to a net loss of $15.0 million for the same period in 2025. The increase in net loss was primarily due to higher research and development expenses and general and administrative costs associated with the company's expansion and public listing. The company's collaboration revenue with Eli Lilly and Company increased to $3.2 million for the three months ended March 31, 2026, from $1.4 million in the same period in 2025.
Key figures
- Eps Beat
- 0
- Revenue
- 3227
- Total Debt
- 70693
- Debt Amount
- 0
- Revenue Yoy
- 1780
- Total Assets
- 576801
- Cash Position
- 371630
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 53404618
- Reverse split ratio
- 1:3.8044
Price after filing
Close on the filing date to close N calendar days later (from $18.27). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.